l e t t e r s
Genome sequencing studies have shown that human malignancies often bear mutations in four or more driver genes 1 , but it is difficult to recapitulate this degree of genetic complexity in mouse models using conventional breeding.
Here we use the CRISPR-Cas9 system of genome editing [2] [3] [4] to overcome this limitation. By delivering combinations of small guide RNAs (sgRNAs) and Cas9 with a lentiviral vector, we modified up to five genes in a single mouse hematopoietic stem cell (HSC), leading to clonal outgrowth and myeloid malignancy. We thereby generated models of acute myeloid leukemia (AML) with cooperating mutations in genes encoding epigenetic modifiers, transcription factors and mediators of cytokine signaling, recapitulating the combinations of mutations observed in patients. Our results suggest that lentivirus-delivered sgRNA:Cas9 genome editing should be useful to engineer a broad array of in vivo cancer models that better reflect the complexity of human disease.
Murine models of myeloid malignancies and other cancers have traditionally been generated using genetic engineering of germline alleles, retroviral overexpression of putative oncogenes, retrovirus-based insertional mutagenesis or RNA interference. Genome sequencing studies have identified a host of recurrently mutated genes 1 , so technologies are now required to examine the function of large numbers of cancer genes and to recapitulate the complex combinations of mutations characteristic of human malignancies. Although short hairpin RNA screens have been used to screen for functionally important genes in malignancy 5, 6 , the use of RNA interference is complicated by incomplete genetic inactivation and substantial off-target effects.
Targeted nucleases, most recently the clustered, regularly interspaced, short palindromic repeats (CRISPR)-CRISPR-associated protein (Cas) systems 2 , have been successfully used to engineer the genomes of multiple model organisms [7] [8] [9] [10] [11] [12] , but their use in primary hematopoietic stem and progenitor cells (HSPC), the disease-initiating cell populations for myeloid malignancies, is complicated by the difficulty of using common nonviral gene transfer methods in these cells.
To perform genome editing with high efficiency in primary HSPCs, and to track the engineered cells in vivo, we generated a modular lentiviral sgRNA:Cas9 vector for modeling of myeloid malignancies by genome editing in primary HSPCs in vivo ( Fig. 1a and Supplementary  Fig. 1 ). This lentiviral vector simultaneously delivers the Streptococcus pyogenes cas9 gene, a chimeric sgRNA and a fluorescent marker, similar to our recently developed system 2, 3, 13, 14 . This enables the targeting of any genomic locus in a broad range of cell types, and consequent nonhomologous end-joining (NHEJ)-mediated gene disruption, by a one-step exchange of the target site (spacer).
We sought to create loss-of-function mutations in eight genes that are recurrently inactivated in myeloid malignancies (Tet2, Runx1, Dnmt3a, Ezh2, Nf1, Smc3, p53 and Asxl1) (Supplementary Methods and Data). We validated the targeting efficacy using a fluorescent reporter, similar to the testing formerly used for genome editing 15 , harboring up to 20 sgRNA:Cas9 target sites as an alternative approach to commonly used endonuclease assays ( Fig. 1a,b ). At least one effective sgRNA was identified for six genes ( Fig. 1c and Supplementary  Table 1 ), whereas no functional sgRNAs were found for p53 and Asxl1. Results for two spacers were confirmed by the standard T7 endonuclease assay, validating efficient cutting at genomic loci ( Fig. 1d) . These findings demonstrate that our lentiviral system achieves efficient cleavage of target sites, and that engineered fluorescent reporter cell lines can provide rapid, quantitative evaluation of spacer efficacy.
Having demonstrated the efficiency of our lentiviral delivery system in vitro, we examined whether we could engineer the genomes of primary mouse HSPCs ex vivo. We isolated Lineage − /Sca1 + /cKit + (LSK) cells, which are enriched for HSPC activity, from mice with knock-in of the Flt3 internal tandem duplication (Flt3-ITD) mutation 16 . Although Flt3-ITD mutations frequently occur in AML, Flt3-ITD knock-in is insufficient to cause AML in mice, and we hypothesized that additional co-operating oncogenic lesions would Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CrIsPr-Cas9 genome editing l e t t e r s induce transformation. Heterozygous Flt3-ITD-expressing LSK cells were transduced with eGFP-expressing sgRNA:Cas9 lentiviral vectors targeting Runx1 or a nontargeting sgRNA ( Fig. 1a ) and were then transplanted into lethally irradiated wild-type (WT) congenic recipient mice. In serial analysis of the peripheral blood of recipient mice, we found that the population of cells expressing Cas9 and the Runx1 sgRNA expanded significantly over a period of 19 weeks in comparison to the population of cells expressing Cas9 and the nontargeting sgRNA (P = 0.03), thus indicating that loss of Runx1 may induce a growth advantage in heterozygous Flt3-ITD-expressing cells in vivo ( Fig. 1e and Supplementary Fig. 2a ).
Detection of eGFP-positive cells 19 weeks after transplant in all HSPC compartments indicated that we transduced long-term repopulating HSCs ( Fig. 1f and Supplementary Fig. 2b,c) . Stable expression of Cas9-eGFP over the 19 weeks in HSPCs and normal differentiation capacity indicates that continuous Cas9 expression at the levels provided does not cause significant toxicity in hematopoietic cells ( Supplementary Fig. 3 ). As further validation of genome modification of HSCs, we performed deep sequencing of the genomic sequence targeted in Runx1 in peripheral blood at serial time points. We identified at least 16 distinct insertions or deletions at the targeted Runx1 site in peripheral blood harvested 5 weeks after transplant that were also present in blood 19 weeks after transplant ( Supplementary Fig. 4 ). The majority of genome modifications were deletions ranging from 1-251 bp. Overall, these results demonstrate that lentiviral delivery of the sgRNA:Cas9 system in HSCs is feasible and well tolerated, and that this system can be employed to edit the genomes of HSCs to interrogate gene function in hematopoiesis.
Because myeloid malignancies, and cancers more broadly, are caused by multiple cooperating genetic lesions (at least 3-4 oncogenic lesions in AML 1 ), we next sought to perform multiplex targeting of cancerassociated genes to induce myeloid malignancy. To facilitate multiplex genome editing, we generated a two-vector system in which Cas9 and an eGFP are delivered from one lentiviral vector, whereas additional sgRNAs and a RFP657 fluorescent marker are delivered by a second lentiviral vector ( Fig. 2a) . The small size of the sgRNA-only vector enables high viral titers and introduction of multiple sgRNAs into a single LSK cell.
We generated a pool of vectors with the single most effective sgRNA for the Tet2, Runx1, Dnmt3a, Nf1, Ezh2 and Smc3 genes. Transduction of LSK cells from C57Bl/6 wild-type mice with the pooled virus, followed by transplantation into lethally irradiated recipient mice, caused significant myeloid skewing of hematopoiesis (P = 0.007) with reduction of B cells (P = 0.001) within the transduced cell population, and leukocytosis in some mice, as compared to the control group, which received LSK cells transduced with control vectors expressing Cas9 and a nontargeting sgRNA ( Fig. 2b) .
To determine the efficacy of multiplex genome editing and to assess the selective pressure for combinations of mutations, we examined the genetics of putative clones in the peripheral blood of mice. Because we used pooled virus expressing different sgRNAs, transduced cells bore different combinations of mutations, and cells with a genotype that drives a competitive advantage gained a clonal dominance as occurs npg l e t t e r s naturally during leukemogenesis. Two-dimensional flow cytometry analysis of eGFP and RFP657 allowed us to detect putatively clonal hematopoietic expansion in vivo (Fig. 2c,d and Supplementary  Fig. 5 ), though some clonal, mutated populations were only GFP dim ( Supplementary Figs. 6 and 7) .
For two mice, we purified populations from peripheral blood based on their eGFP/RFP657 density profile (red gated) by fluorescenceactivated cell sorting (FACS) (Fig. 2c,d) . We examined the targeted genes by PCR amplification, subcloning and sequencing of targeted gene regions. In one mouse, a population expanded gradually over 12 weeks that had mutations in Tet2, Dnmt3a, Runx1 and Nf1 ( Fig. 2c and Supplementary Fig. 8a) , whereas no mutations in Ezh2 and Smc3 were detected. In a second mouse, a population expanded rapidly after transplantation with mutations in Tet2, Runx1, Nf1 and Ezh2 ( Fig. 2d  and Supplementary Fig. 8b) , and no mutations in Dnmt3a and Smc3. In both cases, the detected mutational pattern (detection of two allele Supplementary Fig. 8a .) (d) Another clone was analyzed as in c and was found to have mutations in Tet2, Ezh2, Nf1 and Runx1. Detected mutations at 8 weeks are shown in red box. (Sequences of the deletions are shown in Supplementary Fig. 8b.) l e t t e r s variants) suggests that a single cell was transduced with four separate sgRNAs, resulting in modification of one or both alleles of four tumor suppressor genes. Despite expansion of these clonal populations, no transformation to acute leukemia was observed in these mice during the observation period of up to 30 weeks. Transformation to acute leukemia was observed in a different mouse transduced with the same pool of sgRNAs. A clonal population was detected 4 weeks after transplant, and the mouse was euthanized 6.5 weeks after transplant with mild leukocytosis (white blood cell count: 15.3 × 10 6 /ml; normal: 5-10 ×10 6 /ml) and splenomegaly (436 mg; normal: 80-120 mg). The cells were skewed to the myeloid lineage (Gr1 + /CD11b + ) (Fig. 3a, left panel) with 85% of cells expressing the sgRNA:Cas9 vectors (Fig. 3a, right panel) . Analysis of the targeted genes revealed deletions in Dnmt3a, Ezh2, Smc3 and Nf1 (Supplementary Fig. 9 ). Leukemic cells showed enhanced replating capacity and analysis of methylcellulose colonies from the leukemia confirmed that all mutations occurred within a single clone (Supplementary Fig. 10 and Supplementary Table 2) . The peripheral blood from these mice revealed increased granulocytes and circulating blasts, indicative of leukemic transformation (Fig. 3b, left panel) . Bone marrow histology revealed greater than 20% blast cells and suppression of normal differentiation (Fig. 3b,  right panel, Supplementary Fig. 11a and Supplementary Fig. 12) , consistent with AML.
We next confirmed that the detected mutations had an impact on protein expression and cellular phenotype. Both Ezh2 and Smc3 protein expression were markedly reduced, consistent with the bi-allelic mutations detected in both genes. Nf1 is a negative regulator of the Ras pathway, and we observed derepression of the downstream targets, Erk1 and Erk2, as expected for cells with inactivation of Nf1 (Fig. 3c) . Serial replating of FACS-purified, double-positive eGFP/RFP657-expressing cells indicated greater self-renewal capacity compared to wild-type C57Bl/6 bone marrow cells ( Supplementary  Fig. 10) . Following transplantation into sublethally irradiated secondary transplant recipient mice, we observed robust engraftment of the GFP/RFP657 double-positive mutated cells ( Supplementary  Fig. 11b) . At 8 weeks after transplant two out of five recipient mice developed leukocytosis and succumbed to leukemia at 11-12 weeks after transplant (Supplementary Fig. 11c,d) . Mutated cells in all mice showed a strong differentiation bias, with >90% of the cells belonging to the myeloid lineage ( Fig. 3d,e) . Bone marrow pathology confirmed AML in the secondary transplant recipients ( Fig. 3f  and Supplementary Fig. 11e) .
At 14 weeks following transplantation with the pool of tumor suppressor-targeting sgRNA pooled lentivirus, another primary mouse succumbed to a distinct myeloid leukemia characterized by splenomegaly (412 mg), leukocytosis (white blood cell count: 33.6 × 10 6 /ml), excess myeloid cells in the bone marrow (Supplementary Fig. 13a ), npg l e t t e r s circulating blasts in peripheral blood and diagnostic features of AML in the bone marrow (>20% blasts) ( Supplementary Fig. 13b) . Clonal mutations were identified in Tet2, Dnmt3a, Runx1, Nf1 and Ezh2. None of the mice transplanted with nontargeting sgRNAexpressing cells developed disease during the course of the experiment (Supplementary Fig. 14) . These studies demonstrate that by using lentiviral-delivered sgRNA:Cas9 components, we have engineered models of myeloid malignancy bearing mutations in four to five different genes that can be propagated and studied through serial transplantation.
To examine an alternative set of co-operative mutations, the same pool of sgRNAs targeting leukemia tumor suppressor genes was used to transduce LSK cells from mice with heterozygous knock-in of the Flt3-ITD oncogene allele. Targeting of Runx1 alone did not induce transformation of Flt3-ITD-expressing heterozygous cells (Fig. 1d) . Consistent with the results of pooled tumor suppressor gene targeting in wild-type C57Bl/6 mice, expansion of sgRNA:Cas9transduced, Flt3-ITD-expressing cells was observed over time. In some mice, expression of the sgRNA:Cas9 vector was GFP-dim at 8-10 weeks (Supplementary Fig. 15 ). A total of five out of nine (55%) mice developed disease at 10-16 weeks with leukocytosis and splenomegaly ( Supplementary Fig. 12) . Three of the mice were analyzed further. Bone marrow flow cytometry demonstrated that cells were myeloid biased in each of these mice (Supplementary Figs. 16a  and 17a) . Diagnostic features of AML were evident with an excess of myeloblasts (>20%) in the bone marrow and circulating blast cells in the peripheral blood (Supplementary Figs. 16b, 17b and 18b) . Clonal mutations were detected in three to five genes in the three mice (Supplementary Figs. 16c, 17c and 18c) . Because the mutations were engineered in the Flt3-ITD heterozygous background, AML was generated from primary cells with mutations in four to six leukemia driver genes.
As off-target cleavage by Cas9:sgRNA could potentially contribute to leukemogenesis, we examined leukemias we generated for off-target genome editing 13, 17 . We performed targeted sequencing of the top five off-target sites for each of the sgRNAs in each of four leukemias. None of the off-target sequences had any mutations in any of the leukemias examined, indicating that off-target cleavages are unlikely to be an important contributor to leukemogenesis in our studies (Supplementary Tables 3 and 4) .
Taken together, these studies of lentivirus-delivered Cas9:sgRNA with multiplex sgRNAs demonstrate efficient genome editing in mouse HSPCs. We simultaneously inactivated multiple tumor suppressor genes causing outgrowth of a myeloid clone and transformation to acute leukemia. We describe models with up to five genes modified, with editing of up to ten individual alleles, when a pool of sgRNAs targeting six genes was introduced in primary HSPCs (Fig. 3g) . Although genetic models have recently been generated using Cas9: sgRNA in whole organisms 7-9 , our system enables tissue-specific interrogation of gene function in adult organisms while avoiding potential developmental defects. The genetic complexity thus generated is beyond the capacities of current approaches for engineering murine malignancies and will allow rapid generation of disease models beyond hematopoietic malignancies. Such models are critical for the functional interrogation of novel disease alleles and for the development and preclinical testing of targeted therapies.
The leukemia models generated reflect both the number and functional classes of co-occurring mutations that occur during the pathogenesis of human myeloid malignancies 1, 18 . All of the clones characterized had inactivating mutations in Nf1, a lesion that activates Ras signaling, and the only mutation in the screen that causes activated kinase signaling, a common feature of leukemias and other cancers 18 . Although NF1 mutations are not frequent in AML patients, NF1 was chosen as an amenable target for NHEJ-mediated gene editing and representative for cytokine activation in AML. Nf1 inactivation in mice, however, is insufficient to cause AML and induces a long-latency myeloproliferative disease 19 . We also identified mutations in Ezh2, a gene recently shown to be involved in the differentiation block in AML 20 , in all mice that had myeloid transformation. Inhibition of myeloid differentiation has also been reported after deletion of Dnmt3a 21 , Tet2 (refs. 22, 23 and Runx1 (ref. 24) ), each of which were successfully mutated in our models.
Overall, our studies demonstrate a robust methodology to generate multiple genetic lesions by means of lentivirus-delivered Cas9:sgRNA in a broad range of cells, including the primary adult stem cells that are the disease-initiating population for leukemia. The use of virusbased Cas9:sgRNA will enable the rapid and efficient generation of cancer models that reflect the complex genetics of human disease.
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Methods and any associated references are available in the online version of the paper.
